Bionomics Limited
(ASX:BNO) has announced it will present the results of its trials into an anti-anxiety drug treatment at an upcoming conference in Vienna.
The company will present findings from a phase 1 human clinical trial of its BNC210 drug.
Results indicate that single ascending dosages of the treatment are well tolerated and avoid common side effects that result from the use of standard anxiety drug treatments.
Bionomics is currently evaluating the drug in phase 2 trials for generalized anxiety disorder and post-traumatic stress disorder.
Bionomics Limited reported a net loss of $16.6 million at 30 June 2016.
